Intuitive Surgical, Inc. (ISRG) Stock Analysis
Is ISRG a good investment?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 76.0/100 as of May 26, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Industry-dominant profitability with 66.3% gross margins and 30.9% operating margins significantly exceeding all peers. Main concern: PEG ratio of 2.61 worsened from 2.51, indicating growing overvaluation as stock price rose 4% while growth expectations remained flat.
Investment Summary
ISRG remains a fortress-quality business with exceptional fundamentals: 66.3% gross margins (38% above industry), 30.9% operating margins (121% above peers), ROE of 17.2% (250% above industry), and zero debt with $4.5B cash. However, valuation concerns persist with PEG ratio of 2.61 indicating overvaluation despite 14.2% projected 5-year growth. Stock has risen 4% to $438.10 since prior analysis, worsening the valuation premium. Overwhelmingly positive news sentiment (97/100) supports platform expansion potential with da Vinci 5 and Ion systems driving TAM growth.
Key Strengths
- Industry-dominant profitability with 66.3% gross margins and 30.9% operating margins significantly exceeding all peers
- Fortress balance sheet with zero debt and $4.5B cash providing unmatched financial flexibility and recession resilience
- Overwhelmingly positive news sentiment (97/100) highlighting platform expansion potential and successful product innovation
Key Concerns
- PEG ratio of 2.61 worsened from 2.51, indicating growing overvaluation as stock price rose 4% while growth expectations remained flat
- Growth deceleration from historical 25.9% EPS growth to projected 13.4% forward growth signals business maturation challenges
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ISRG demonstrates industry-leading profitability with gross margins of 66.3% vs industry 47.9%, operating margins of 30.9% vs 14.0%, and net margins of 28.1% vs 4.8%. ROE of 17.2% significantly exceeds industry 4.9%. Balance sheet remains pristine with zero debt vs industry average 0.62 D/E ratio and $4.5B cash providing strategic flexibility. Growth metrics show 23% revenue growth and 18.8% earnings growth historically, but forward projections moderate to 13.4% next year and 14.2% five-year. Primary concern is PEG ratio of 2.61 indicating stock trades at 161% premium to growth rate, suggesting overvaluation despite quality. Additional metrics: PE Ratio: 53.14
News Sentiment
Intuitive Surgical is riding a wave of innovation that could reshape its growth trajectory for years to come. The medical robotics giant has been making headlines with its expanding platform capabilities, particularly around its da Vinci 5 system and Ion lung cancer platform. Recent coverage highlights how ISRG's SP Platform represents a potential 'next TAM expansion driver,' suggesting the company could significantly broaden its addressable market beyond traditional robotic surgery procedures. The Ion Platform is being positioned as 'a major growth engine in lung cancer care,' tapping into one of healthcare's most critical treatment areas. Adding to the optimism, analysts are spotlighting ISRG as one of the 'healthcare giants' best positioned to benefit from aging population trends - a demographic shift that promises sustained demand for advanced medical technologies. The company has also been exploring artificial intelligence integration to tackle industry challenges, positioning itself at the forefront of medical technology evolution. Despite a 20% year-to-date decline creating some investor concern, the overwhelming sentiment remains bullish on ISRG's long-term prospects. The convergence of an aging population, advancing surgical robotics, and expanding treatment applications creates a compelling growth narrative that has investors and analysts increasingly confident in the company's ability to maintain its market leadership while capturing new opportunities.
Risk Assessment
Primary risk is valuation premium with PEG of 2.61 leaving limited margin of safety. Growth deceleration from 25.9% to 13.4% could disappoint growth-oriented investors. However, exceptional business quality, zero debt, and $4.5B cash provide significant downside protection. Regulatory changes in healthcare or competitive threats to robotic surgery dominance represent additional risks.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ISRG a halal stock?
No, Intuitive Surgical, Inc. (ISRG) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ISRG?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 76.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ISRG a good investment?
According to Plutrex AI, ISRG has a Buy rating (76.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ISRG?
US stocks like ISRG can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ISRG?
Plutrex AI identifies the main risks for ISRG by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.